Imugene (ASX:IMU) secures deal to evaluate its cancer vaccine

Latest Company News - Finance News Network

English - November 15, 2021 23:10 - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Stocks of the Hour: Incitec Pivot, Woodside Petroleum & Mesoblast

Next Episode: Beach Energy (ASX:BPT) appoints acting chief financial officer

16 Nov 2021 - Bio-tech company Imugene (ASX: IMU) has announced a new clinical trial supply agreement to evaluate the safety and efficiency of Imugene’s HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer.